PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'The Francis Crick Institute, London, UK.\', \'Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King\'s College London, London, UK.\', \'Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King\'s College London, London, UK; UCL Cancer Institute, University College London, London, UK.\', \'Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Breast Cancer Now Research Unit, King\'s College London, London, UK.\', \'Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King\'s College London, London, UK.\', \'Department of Infectious Diseases, School of Immunology and Microbial Sciences, King\'s College London, London, UK.\', \'Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK.\', \'Breast Cancer Now Research Unit, King\'s College London, London, UK.\', \'Guy\'s and St Thomas\' NHS Foundation Trust, London, UK.\', \'Department of Haematological Medicine, King\'s College Hospital, London, UK.\', \'Regeneration Group, Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King\'s College London, London, UK.\', \'Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King\'s College London, London, UK; Department of Plastic and Reconstructive Surgery, Royal Free NHS Foundation Trust, London, UK.\', \'Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King\'s College London, London, UK; Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK.\', \'Clinical Trials Unit, King\'s College London, London, UK.\', \'Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Guy\'s and St Thomas\' NHS Foundation Trust, London, UK.\', \'Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Department of Haematological Medicine, King\'s College Hospital, London, UK.\', \'Institute of Molecular Biology and Pathology, National Research Council of Italy, Rome, Italy.\', \'The Francis Crick Institute, London, UK; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King\'s College London, London, UK.\', \'Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King\'s College London, London, UK; Breast Cancer Now Research Unit, King\'s College London, London, UK; Guy\'s and St Thomas\' NHS Foundation Trust, London, UK. Electronic address: sheeba.irshad@kcl.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1470-2045(21)00213-810.1016/S1470-2045(21)00213-8
?:doi
?:hasPublicationType
?:journal
  • The Lancet. Oncology
is ?:pmid of
?:pmid
?:pmid
  • 33930323
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33930323>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33930323>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all